-
Jan 4, 2024 | 
outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Peter H. Calcott |Steve Kemler |Louis Garguilo
Get more pharma outsourcing insight with our FREE newsletter
Newsletter
| January 4, 2024
BEST OF INDUSTRY INSIGHTSConnect With Outsourced Pharma:
-
Jan 3, 2024 | 
outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Peter H. Calcott |Ryan Chandanais |Louis Garguilo
Get more pharma outsourcing insight with our FREE newsletter
Newsletter
| January 3, 2024
BEST OF INDUSTRY INSIGHTSConnect With Outsourced Pharma:
-
Jan 2, 2024 | 
outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Peter H. Calcott |Ryan Chandanais |Louis Garguilo
Get more pharma outsourcing insight with our FREE newsletter
Newsletter
| January 2, 2024
BEST OF INDUSTRY INSIGHTSConnect With Outsourced Pharma:
-
Nov 16, 2023 | 
biosimilardevelopment.com | Amanda McFarland |Ryan Murray |Peter Alexander |Phillip Ramsey
This article focuses on the formality concept discussed in the revision of ICH Q9 Quality Risk Management released earlier in 2023. The authors provide a helpful overview of what risk tools are appropriate to use during certain types of scenarios, and what the team composition should look like. The principles of an effective technology transfer can apply at every stage of the drug development life cycle for biotech companies of every size.
-
Oct 31, 2023 | 
outsourcedpharma.com | Louis Garguilo |Peter Alexander |Phillip Ramsey |Peter H. Calcott
Inside 2023 Meeting On The Mesa With ARM's COO, Rita Johnson-GreeneAlliance for Regenerative Medicine's COO, Rita Johnson-Greene, joined Cell & Gene: The Podcast host, Erin Harris, in person at the 2023 Meeting on the Mesa to discuss this year's event. Johnson-Greene also shared what's ahead for 2024 as the event moves to a new location. They discussed major topics and trends at the event as well as ARM's GROW internship program.
-
Oct 23, 2023 | 
outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Jody Staggs |SWK Holdings |Louis Garguilo
We’ve all heard how important speed, time to milestone, and quality are when choosing a CTDMO. Our “Why choosing a client-centric CTDMO is critical when outsourcing biomanufacturing projects” infographic details the top five considerations and the complexities biopharma companies such as yours consider when selecting a CTDMO. Evaluate the infographic against your current challenges and share with us. We’re here. We’re built to serve. Download infographic.
-
Oct 11, 2023 | 
outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Nathan Dormer |Tim Rich |Louis Garguilo
Accelerated development schedules, quicker pathways to approvals, emerging technologies and therapies, more outsourcing than ever — often located across the globe. All this presents opportunity, and steepening challenges for your quality and regulatory teams. Join the next Outsourced Pharma Live, where our panel of experts will offer strategies to meet regulatory challenges. This webinar is free to attend thanks to the support of Ajinomoto Bio-Pharma Services.
-
Sep 19, 2023 | 
cellandgene.com | Peter Alexander |Phillip Ramsey
Guest Column
| September 19, 2023
By Peter Alexander and Phillip Ramsey
The life cycle of pharmaceutical development always requires the transfer of the production process and analytical methods from development into GMP manufacturing and quality control laboratories.
-
Sep 19, 2023 | 
lifescienceleader.com | Peter Alexander |Phillip Ramsey
Guest Column
| September 19, 2023
By Peter Alexander and Phillip Ramsey
The life cycle of pharmaceutical development always requires the transfer of the production process and analytical methods from development into GMP manufacturing and quality control laboratories.
-
Sep 19, 2023 | 
bioprocessonline.com | Peter Alexander |Phillip Ramsey
Guest Column
| September 19, 2023
By Peter Alexander and Phillip Ramsey
The life cycle of pharmaceutical development always requires the transfer of the production process and analytical methods from development into GMP manufacturing and quality control laboratories.
